

# Naoto T Ueno

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2474462/naoto-t-ueno-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330  
papers

13,492  
citations

56  
h-index

106  
g-index

355  
ext. papers

15,883  
ext. citations

6.5  
avg, IF

6.01  
L-index

#	Paper	IF	Citations
330	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , <b>2016</b> , 534, 47-54	50.4	1193
329	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i> , <b>2001</b> , 97, 631-7	2.2	508
328	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5533-40	12.9	476
327	Bone imaging in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2942-53	2.2	441
326	A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1873-81	27.4	414
325	Role of epidermal growth factor receptor in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 136, 331-45	4.4	371
324	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2753-62	2.2	295
323	Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 593-9	2.2	295
322	Inflammatory breast cancer: the disease, the biology, the treatment. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2010</b> , 60, 351-75	220.7	233
321	Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. <i>Cancer Research</i> , <b>2004</b> , 64, 2502-8	10.1	223
320	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1997</b> , 40, 321-9	3.5	203
319	Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3422-33	2.2	182
318	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 729-34	2.2	174
317	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2526-34	6.1	165
316	Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 18707-12	11.5	163
315	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , <b>2011</b> , 13, R67	8.3	161
314	Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. <i>Journal of Cancer</i> , <b>2010</b> , 1, 80-92	4.5	161

313	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , <b>2017</b> , 543, 714-718	50.4	157
312	Prognostic value of nodal ratios in node-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2910-6	2.2	157
311	Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. <i>Cancer</i> , <b>2007</b> , 110, 1436-44	6.4	153
310	Inflammatory breast cancer biology: the tumour microenvironment is key. <i>Nature Reviews Cancer</i> , <b>2018</b> , 18, 485-499	31.3	133
309	Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3303-11	2.2	126
308	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , <b>2003</b> , 102, 3829-36	2.2	125
307	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. <i>Journal of Controlled Release</i> , <b>2004</b> , 97, 357-69	11.7	124
306	Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. <i>Lancet Oncology</i> , <b>2009</b> , 10, 606-14	21.7	120
305	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. <i>Haematologica</i> , <b>2008</b> , 93, 257-64	6.6	117
304	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , <b>2007</b> , 7, 34-42	3	115
303	Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1155-68	7.9	111
302	Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1266-1273	13.4	109
301	Inflammatory breast cancer: what we know and what we need to learn. <i>Oncologist</i> , <b>2012</b> , 17, 891-9	5.7	108
300	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. <i>Cancer</i> , <b>2011</b> , 117, 1819-26	6.4	102
299	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. <i>Cancer Research</i> , <b>2007</b> , 67, 5779-88	10.1	102
298	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4685-96	12.9	99
297	Targeting EGFR in Triple Negative Breast Cancer. <i>Journal of Cancer</i> , <b>2011</b> , 2, 324-8	4.5	98
296	Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6639-48	12.9	95

295	Future directions of bone-targeted therapy for metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 641-51	19.4	85
294	Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2018-24	2.2	84
293	Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/ $\beta$ -catenin signaling. <i>Stem Cells</i> , <b>2012</b> , 30, 2366-77	5.8	83
292	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. <i>Oncogene</i> , <b>1997</b> , 15, 953-60	9.2	82
291	Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. <i>International Journal of Cancer</i> , <b>2011</b> , 129, 417-23	7.5	81
290	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. <i>Oncotarget</i> , <b>2015</b> , 6, 12890-908	3.3	80
289	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 440	8.3	77
288	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , <b>2012</b> , 17, 96-104	4.2	72
287	High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3214-23	2.2	72
286	Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1675-83	5.7	70
285	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0132710	3.7	69
284	Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2012</b> , 12, 264-9	3	67
283	High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e83113	3.7	65
282	Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. <i>Cancer</i> , <b>2001</b> , 92, 1775-82	6.4	63
281	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 1846-50	6.1	62
280	Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2420-2428	10.3	61
279	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. <i>Clinical Breast Cancer</i> , <b>2007</b> , 7, 471-9	3	60
278	PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. <i>Cancer Research</i> , <b>2008</b> , 68, 9302-10	10.1	59

277	FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1111-9	5.7	58
276	Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , <b>2012</b> , 3, 369-80	4.5	58
275	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. <i>Oncotarget</i> , <b>2016</b> , 7, 82482-82492	3.3	57
274	Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. <i>Cancer</i> , <b>2011</b> , 117, 5476-84	6.4	56
273	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. <i>Breast Cancer Research</i> , <b>2009</b> , 11, R12	8.3	55
272	Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 2168-77	6.1	55
271	Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. <i>Lancet Oncology</i> , <b>2017</b> , 18, e228-e232	21.7	54
270	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 785-95	4.4	54
269	TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. <i>Cancer Research</i> , <b>2013</b> , 73, 6516-25	10.1	53
268	Improvement of survival and prospect of cure in patients with metastatic breast cancer. <i>Breast Cancer</i> , <b>2012</b> , 19, 191-9	3.4	53
267	Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. <i>Oncologist</i> , <b>2011</b> , 16, 155-64	5.7	53
266	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , <b>2015</b> , 1, 1311-8	13.4	52
265	High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3224-31	2.2	52
264	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	52
263	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2773-81	6.1	51
262	Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. <i>Stem Cells Translational Medicine</i> , <b>2014</b> , 3, 849-56	6.9	51
261	<sup>18</sup> F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. <i>Journal of Nuclear Medicine</i> , <b>2010</b> , 51, 1213-8	8.9	51
260	Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 131-4	4.5	51

259	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 152, 407-16	4.4	50
258	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. <i>Journal of Cancer</i> , <b>2018</b> , 9, 1437-1447	4.5	45
257	Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. <i>Cancer</i> , <b>2014</b> , 120, 1319-28	6.4	45
256	Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. <i>Future Oncology</i> , <b>2009</b> , 5, 1585-603	3.6	45
255	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2017</b> , 9, 493-511	5.4	44
254	Molecular targets for treatment of inflammatory breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2009</b> , 6, 387-94	19.4	44
253	The role of inflammation in inflammatory breast cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2014</b> , 816, 53-73	3.6	43
252	Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. <i>Oncotarget</i> , <b>2016</b> , 7, 28329-39	3.3	43
251	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1025-1035	12.5	42
250	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 42	8.3	42
249	Genomic and expression analysis of microdissected inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 138, 761-72	4.4	41
248	Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. <i>Cancer Research</i> , <b>2002</b> , 62, 6712-6	10.1	41
247	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 154, 495-508	4.4	40
246	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1207-1213	13.4	39
245	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R112	8.3	39
244	Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. <i>Cancer Science</i> , <b>2009</b> , 100, 2275-82	6.9	39
243	Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. <i>Cell Reports</i> , <b>2014</b> , 7, 488-500	10.6	38
242	Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. <i>Hematology/Oncology Clinics of North America</i> , <b>1999</b> , 13, 1041-57, vii-viii	3.1	38

241	ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2689-2701	6.1	36
240	Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 889-95	4	35
239	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 146, 259-72	4.4	34
238	Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2012</b> , 83, 1381-6	4	34
237	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 2	8.3	33
236	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 93	8.3	33
235	PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1802-11	12.9	33
234	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , <b>2014</b> , 5, 745-53	4.5	32
233	The antihelminthic drug pyrvinium pamoate targets aggressive breast cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e71508	3.7	32
232	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 35656-35668	3.3	32
231	Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. <i>Breast Journal</i> , <b>2010</b> , 16, 327-30	1.2	31
230	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , <b>2016</b> , 7, 18531-40	3.3	31
229	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , <b>2016</b> , 29, 330-46	9.8	30
228	Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 1465-74	4.7	30
227	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 463-479	5.9	29
226	A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2375-82	6.1	29
225	Challenges and perspective of drug repurposing strategies in early phase clinical trials. <i>Oncoscience</i> , <b>2015</b> , 2, 576-80	0.8	29
224	Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. <i>Surgical Clinics of North America</i> , <b>2018</b> , 98, 787-800	4	29

223	High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 91, 1072-80	4	28
222	A prospective study of bone tumor response assessment in metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2013</b> , 13, 24-30	3	28
221	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 14897-14911	3.3	28
220	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 12780-12785	11.5	27
219	Epidemiological risk factors associated with inflammatory breast cancer subtypes. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 359-66	2.8	27
218	The medical treatment of inflammatory breast cancer. <i>Seminars in Oncology</i> , <b>2008</b> , 35, 64-71	5.5	27
217	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 2604-14	3.3	27
216	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. <i>American Journal of Clinical Pathology</i> , <b>2015</b> , 144, 713-21	1.9	26
215	Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 78-89		26
214	Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4780-4792	12.9	25
213	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204513	3.7	25
212	Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. <i>Cancer Research</i> , <b>2005</b> , 65, 8406-13	10.1	24
211	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 67904-67917	3.3	24
210	JNK Signaling in Stem Cell Self-Renewal and Differentiation. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	23
209	Bone Metastasis of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1152, 105-129	3.6	23
208	Survival Outcomes by Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	23
207	Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 137, 523-31	4.4	22
206	Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. <i>Cancer</i> , <b>2015</b> , 121, 4324-32	6.4	22



205	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2015</b> , 38, 242-7	2.7	22
204	Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 227-35	6.1	22
203	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	21
202	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, e73-e77	3	21
201	MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 360-9	6.1	21
200	Identification of frequent somatic mutations in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 163, 263-272	4.4	20
199	MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 95, 791-9	4	20
198	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 58	12.8	20
197	Gene signature-guided dasatinib therapy in metastatic breast cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5265-71	12.9	20
196	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 345-351	4.3	20
195	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 164, 57-67	4.4	19
194	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. <i>Carcinogenesis</i> , <b>2016</b> , 37, 1180-1189	4.6	19
193	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2981-2988	3.1	19
192	Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. <i>Gynecologic Oncology</i> , <b>2011</b> , 122, 641-7	4.9	19
191	The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2004</b> , 10, 794-804	4.7	19
190	Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1039-46	6.1	19
189	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , <b>2017</b> , 123, 2422-2431	6.4	18
188	Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. <i>Plastic and Reconstructive Surgery</i> , <b>2015</b> , 135, 262e-269e	2.7	18

187	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. <i>Journal of Cancer</i> , <b>2017</b> , 8, 2026-2032	4.5	18
186	E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. <i>Breast Cancer</i> , <b>2001</b> , 8, 285-93	3.4	18
185	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. <i>American Journal of Hematology</i> , <b>2001</b> , 67, 227-33	7.1	18
184	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 76362-76373	3.3	18
183	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. <i>Nature Communications</i> , <b>2021</b> , 12, 3528	17.4	18
182	Patient reported outcomes can improve performance status assessment: a pilot study. <i>Journal of Patient-Reported Outcomes</i> , <b>2019</b> , 3, 41	2.6	17
181	Androgen receptor expression on circulating tumor cells in metastatic breast cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185231	3.7	17
180	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. <i>American Journal of Clinical Pathology</i> , <b>2018</b> , 149, 253-261	1.9	17
179	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , <b>2018</b> , 77, 121-129	3.7	17
178	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835919866065	5.4	17
177	Latest biopsy approach for suspected metastases in patients with breast cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 711-9	19.4	17
176	Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. <i>Cancer</i> , <b>2012</b> , 118, 2039-47	6.4	17
175	Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. <i>Oncologist</i> , <b>2012</b> , 17, 233-8	5.7	17
174	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , <b>2020</b> , 80, 1304-1315	10.1	16
173	CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 9427	4.9	16
172	(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1809-16	8.8	16
171	Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. <i>Journal of Cancer</i> , <b>2011</b> , 2, 435-42	4.5	16
170	Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser <sup>117</sup> p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 3090-9	6.1	16

169	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1239-41	1.9	16
168	A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells <b>2013</b> , 1, 59-66		16
167	Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. <i>Molecular Therapy - Oncolytics</i> , <b>2017</b> , 6, 1-9	6.4	16
166	Neoadjuvant nab-paclitaxel in the treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 156, 427-440	4.4	16
165	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). <i>Neoplasia</i> , <b>2017</b> , 19, 564-573	6.4	15
164	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 1105-1112	8.7	15
163	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. <i>SpringerPlus</i> , <b>2014</b> , 3, 166		15
162	Breast Cancer Biomarkers: Utility in Clinical Practice. <i>Current Breast Cancer Reports</i> , <b>2013</b> , 5, 284	0.8	15
161	Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1099-111	6.1	15
160	Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. <i>Oncogene</i> , <b>2019</b> , 38, 2135-2150	9.2	15
159	Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. <i>Haematologica</i> , <b>2005</b> , 90, 1725-6	6.6	15
158	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 509-514	8.7	14
157	Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. <i>Clinical Breast Cancer</i> , <b>2014</b> , 14, e81-8	3	14
156	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , <b>2015</b> , 6, 1306-19	4.5	14
155	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , <b>2015</b> , 6, 310-8	4.5	14
154	Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 100, 449-57	4.8	14
153	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152585	3.7	14
152	Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. <i>Cancer Medicine</i> , <b>2017</b> , 6, 2515-2522	4.8	13

151	Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. <i>Oncologist</i> , <b>2014</b> , 19, 909-14	5.7	13
150	ABC conceptual model of effective multidisciplinary cancer care. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 544-7	19.4	13
149	Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 772-82	5.7	13
148	Primary malignant teratoma of the thyroid gland: report and discussion of two cases. <i>Head and Neck</i> , <b>1998</b> , 20, 649-53	4.2	13
147	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 8537	4.9	13
146	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , <b>2020</b> , 14, 504-519	7.9	13
145	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. <i>Journal of Cancer</i> , <b>2018</b> , 9, 3640-3646	4.5	13
144	What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 31-3	4.7	12
143	Information sharing and case conference among the multidisciplinary team improve patients' perceptions of care. <i>Open Nursing Journal</i> , <b>2011</b> , 5, 79-85	0.6	12
142	Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222336	3.7	11
141	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream <sup>®</sup> in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0229903	3.7	11
140	BRCA mutations in women with inflammatory breast cancer. <i>Cancer</i> , <b>2018</b> , 124, 466-474	6.4	11
139	Thrombocytosis as a prognostic factor in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 166, 819-832	4.4	11
138	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , <b>2006</b> , 108, 315-315 <sup>2</sup>	12.2	11
137	Inflammatory breast cancer cells are characterized by abrogated TGF $\beta$ -dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 180, 385-395	4.4	11
136	Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , <b>2020</b> , 9, 1025-1032	4.8	11
135	Elevated serum levels of sialyl Lewis X (sLe) and inflammatory mediators in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 176, 545-556	4.4	10
134	Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 175, 339-351	4.4	10

133	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2687-99	6.1	10
132	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. <i>Cancer Letters</i> , <b>2015</b> , 356, 374-381	9.9	10
131	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. <i>Journal of Cancer</i> , <b>2019</b> , 10, 3344-3351	4.5	10
130	Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. <i>International Journal of Clinical Oncology</i> , <b>2011</b> , 16, 596-600	4.2	10
129	Targeted therapy in inflammatory breast cancer. <i>Cancer</i> , <b>2010</b> , 116, 2758-9	6.4	10
128	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , <b>2017</b> , 8, 70481-70495	3.3	10
127	Body composition and breast cancer risk and treatment: mechanisms and impact. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 186, 273-283	4.4	10
126	Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. <i>Communications Biology</i> , <b>2021</b> , 4, 72	6.7	10
125	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2015</b> , 15, 458-66	3	9
124	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , <b>2017</b> , 8, 2004-2009	4.5	9
123	A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. <i>Clinical Breast Cancer</i> , <b>2013</b> , 13, 460-4	3	9
122	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10 Anniversary Conference. <i>Journal of Cancer</i> , <b>2017</b> , 8, 3607-3614	4.5	9
121	MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 489, 484-489	3.4	9
120	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. <i>Journal of Cancer</i> , <b>2016</b> , 7, 947-56	4.5	9
119	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 21-7	5.7	9
118	Impact of androgen receptor expression in flouxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 160, 101-109	4.4	9
117	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. <i>Cancer</i> , <b>2017</b> , 123, 2618-2625	6.4	8
116	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. <i>Clinical Breast Cancer</i> , <b>2018</b> , 18, e1283-e1288	3	8

115	Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 956-657		8
114	Targeting Signaling Pathways in Inflammatory Breast Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
113	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 1588-1595	3.6	8
112	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204372	3.7	8
111	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , <b>2019</b> , 114, 167-174	4.7	7
110	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1045-1052	4.5	7
109	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 169, 615-623	4.4	7
108	Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2009</b> , 9, 173-7	3	7
107	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231953	3.7	6
106	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , <b>2018</b> , 124, 2299-2305	6.4	6
105	Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. <i>Cancer</i> , <b>2014</b> , 120, 1775-9	6.4	6
104	Serum HER2 levels determined by two methods in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , <b>2012</b> , 17, 55-62	4.2	6
103	Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. <i>Biology of Blood and Marrow Transplantation</i> , <b>2003</b> , 9, 330-40	4.7	6
102	High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. <i>Clinical Breast Cancer</i> , <b>2000</b> , 1, 197-209; discussion 210	3	6
101	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 839-853	5.2	6
100	NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	6
99	Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. <i>Clinical Breast Cancer</i> , <b>2015</b> , 15, 37-42	3	5
98	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1009-1017	4.5	5

97	Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. <i>PLoS ONE</i> , <b>2018</b> , 13, e0195932	3.7	5
96	Zevalin /BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. <i>Blood</i> , <b>2007</b> , 110, 620-620	2.2	5
95	Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 6872-6882	3.3	5
94	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 4603-4612	3.1	5
93	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	5
92	Cooperative Effect of Oncogenic and in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 399-412	6.1	5
91	Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 296-306	6.1	5
90	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 4265-4274	3.1	5
89	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. <i>Clinical Biomechanics</i> , <b>2018</b> , 56, 61-69	2.2	5
88	The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. <i>Journal of Pathology</i> , <b>2020</b> , 251, 63-73	9.4	4
87	Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. <i>Cells</i> , <b>2020</b> , 9,	7.9	4
86	Survivorship and Advocacy in Inflammatory Breast Cancer. <i>Journal of Cancer</i> , <b>2018</b> , 9, 1430-1436	4.5	4
85	In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 165, 779-781	4.4	4
84	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , <b>2013</b> , 4, 679-85	4.5	4
83	Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. <i>Journal of Cancer</i> , <b>2013</b> , 4, 697-702	4.5	4
82	Metastasis in the breast mimicking inflammatory breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e202-6	2.2	4
81	Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 975-85	4.7	4
80	Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. <i>Breast Cancer Research</i> , <b>2007</b> , 9, R41	8.3	4

79	High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 37, 929-35	4.4	4
78	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. <i>Transplant Infectious Disease</i> , <b>2001</b> , 3, 29-33	2.7	4
77	Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 171, 501-511	4.4	4
76	Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 579-586	6.4	4
75	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Oncotmunology</i> , <b>2021</b> , 10, 1929724	7.2	4
74	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , <b>2020</b> , 20, 430	4.8	3
73	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. <i>Journal of Cancer</i> , <b>2017</b> , 8, 1726-1732	4.5	3
72	Impact of clinical trial on survival outcomes. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 159, 273-81	4.4	3
71	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. <i>Therapeutic Advances in Medical Oncology</i> , <b>2018</b> , 10, 1758835918786858	5.4	3
70	Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 609-609	2.2	3
69	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 22242	4.9	3
68	Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. <i>Oncologist</i> , <b>2019</b> , 24, 1322-1330	5.7	3
67	Update on systemic treatment for newly diagnosed inflammatory breast cancer. <i>Journal of Advanced Research</i> , <b>2021</b> , 29, 1-12	13	3
66	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 89, 64-71	7.5	3
65	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
64	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2752-2765	7.9	3
63	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. <i>Practical Radiation Oncology</i> , <b>2019</b> , 9, 402-409	2.8	2
62	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. <i>Journal of Cancer</i> , <b>2019</b> , 10, 2635-2642	4.5	2



61	Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170081	3.7	2
60	Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. <i>Breast</i> , <b>2018</b> , 39, 148-149	3.6	2
59	Bone Metastases <b>2012</b> , 591-609		2
58	Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. <i>International Journal of Hematology</i> , <b>2009</b> , 90, 627-634	2.3	2
57	Graft-versus-breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3846-7	2.2	2
56	Abstract P3-01-10: NdrG1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis <b>2020</b> ,		2
55	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. <i>Blood</i> , <b>2004</b> , 104, 2301-2301	2.2	2
54	Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 11501-11501	2.2	2
53	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance		2
52	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. <i>Genome Medicine</i> , <b>2021</b> , 13, 70	14.4	2
51	PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	2
50	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 8610-8621	3.1	2
49	Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, 177-183	2.3	2
48	Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. <i>Bioorganic and Medicinal Chemistry</i> , <b>2021</b> , 32, 116013	3.4	2
47	Inflammatory breast cancer appearance at presentation is associated with overall survival. <i>Cancer Medicine</i> , <b>2021</b> , 10, 6261-6272	4.8	2
46	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
45	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases <b>1998</b> , 20, 649		2
44	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	2

43	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 583-601	5.2	1
42	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. <i>Oncologist</i> , <b>2020</b> , 25, e909-e919	5.7	1
41	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 18-29	4.5	1
40	Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin's Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.. <i>Blood</i> , <b>2004</b> , 104, 1654-1654	2.2	1
39	Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. <i>Blood</i> , <b>2004</b> , 104, 5239-5239	2.2	1
38	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. <i>Blood</i> , <b>2009</b> , 114, 868-868	2.2	1
37	Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 532-532	2.2	1
36	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11532-11532	2.2	1
35	Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 559-559	2.2	1
34	Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1087-1087	2.2	1
33	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. <i>PLoS ONE</i> , <b>2021</b> , 16, e0250057	3.7	1
32	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 455-461	4.4	1
31	Inflammatory Breast Cancer at the Extremes of Age. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 5626-5634	3.1	1
30	Estrogen Receptor Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 2399-2414	10.1	1
29	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2000368	3.6	1
28	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling.. <i>Nature Communications</i> , <b>2022</b> , 13, 1791	17.4	1
27	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 12	7.8	0
26	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. <i>Blood</i> , <b>2008</b> , 112, 5440-5440	2.2	0

25	The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 183, 729-739	4.4	○
24	Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 189, 333-345	4.4	○
23	Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''. <i>British Journal of Cancer</i> , <b>2017</b> , 116, e11	8.7	
22	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. <i>Cancer</i> , <b>2018</b> , 124, 866	6.4	
21	The Emerging Impact of Social Media on Cancer Patient Education in Japan. <i>Oncologist</i> , <b>2018</b> , 23, e105-e106	4.6	
20	Lapatinib in the Treatment of Breast Cancer. <i>Clinical Medicine Therapeutics</i> , <b>2009</b> , 1, CMT.S52		
19	Signaling Pathways in Inflammatory Breast Cancer <b>2012</b> , 151-160		
18	Stem Cell Transplantation for Metastatic and High-Risk Nonmetastatic Breast Cancer: A Novel Treatment Approach <b>2008</b> , 387-410		
17	Trials and Tribulations in Developing Clinical Trials of Gene Therapy <b>2007</b> , 387-398		
16	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. <i>Blood</i> , <b>2007</b> , 110, 48-48	2.2	
15	Inflammatory and Locally Advanced Breast Cancer <b>2016</b> , 411-435		
14	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. <i>Blood</i> , <b>2009</b> , 114, 3213-3213	2.2	
13	Systemic and Targeted Therapy <b>2012</b> , 85-99		
12	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study <b>2012</b> , 225-242		
11	High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer <b>2012</b> , 127-138		
10	Bone Metastasis of Breast Cancer <b>2013</b> , 189-209		
9	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. <i>Seminars in Ultrasound, CT and MRI</i> , <b>2021</b> , 42, 164-183	1.7	
8	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.. <i>Scientific Reports</i> , <b>2022</b> , 12, 2478	4.9	

- 7 Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases.. *World Journal of Oncology*, **2021**, 12, 183-194 16.7
- 6 Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research **2020**, 15, e0231953
- 5 Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research **2020**, 15, e0231953
- 4 Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research **2020**, 15, e0231953
- 3 Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research **2020**, 15, e0231953
- 2 Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research **2020**, 15, e0231953
- 1 Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research **2020**, 15, e0231953